Table 3.

Metabolic side effects in a long-term study⁴⁹ evaluated at the end point (24 weeks)

Treatment group	Mean change from baseline (kg)	% patients with weight gain (≥7%)	% patients with increased triglycerides (>200 mg/dL)
45 mg/4 wk	−0.95	8	3.4
150 mg/2 wk	0.67	15	6.5
405 mg/4 wk	0.89	16	9.8
300 mg/2 wk	1.70	21	24.5
Oral olanzapine (mean dose, 14.3 mg/d)	1.30	21	13.8